NVGN News 3.91 Novogen Ltd (NVGN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Novogen Ltd (NVGN) 3.91 $NVGN

Novogen and CanTx's experimental drug Trx-1 passes important test to fight abdominal cancers
M2 - Wed Mar 19, 7:56AM CDT
Australian biotechnology company Novogen (ASX:NRT)(NASDAQ:NVGN) revealed on Tuesday that its lead candidate drug, Trx-1, has demonstrated a potent anti-cancer effect in mice xenografted with human ovarian cancer stem cells in partnership with CanTx.

Novogen and CanTx Experimental Drug, Trx-1, Proves Effective in Vivo
PR Newswire - Tue Mar 18, 7:00AM CDT
Novogen Limited [ASX:NRT; NASDAQ:NVGN] and its joint venture company with Yale University, CanTx Inc, today announced an important milestone with lead candidate drug, Trx-1, demonstrating a potent anti-cancer effect in mice xenografted with human ovarian cancer stem cells.

Novogen to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York
PR Newswire - Wed Mar 12, 10:00AM CDT
Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced that Graham Kelly, Ph.D., Executive Director and Chief Executive Officer, will present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum. Dr. Kelly's presentation will take place at 2:30 p.m. on Wednesday, March 19, 2014 at the New York Academy of Sciences in New York City.

Novogen Selected to Present at Cavendish Global Health Impact Forum
PR Newswire - Mon Mar 10, 12:27PM CDT
Novogen Limited (ASX: 'NRT'; NASDAQ: 'NVGN' , an oncology drug development company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 at the United Nations Headquarters in New York. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences.

Novogen Appoints New Board Members and Strategic Advisor to Support Transition to Clinical Development and Growing International Presence
PR Newswire - Tue Mar 04, 5:00AM CST
Novogen Limited (ASX:NRT; NASDAQ:NVGN]), an oncology drug development company, today announced key new appointments to guide the company in its transition into a clinical-stage company with a growing U.S. presence and an investor base in the U.S. and Australia. Professor Peter Gunning, PhD, a leading world authority on the cytoskeleton, and Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive, join the Novogen board of directors as non-executive directors. David W. Gryska, an industry expert with over 20 years of experience in management at many of the top U.S. biotechnology companies, will serve as a strategic advisor to the board with a focus on U.S. capital markets and as a U.S. shareholder liaison.

New Sears Appliance & Hardware Store Opens in Huntsville
GlobeNewswire - Fri Feb 21, 2:30PM CST
Sears Hometown and Outlet Stores, Inc. (Nasdaq:SHOS) announces the opening of a new Sears Appliance & Hardware Store located at 1702 11 Street in Huntsville, Texas.

Direct Energy Revenue Up 28% in 2013
PR Newswire - Thu Feb 20, 1:15AM CST
Direct Energy, North America's largest competitive energy and energy-related services company, today announced gross revenue for the full year 2013 of US $11.4 billion (£7.3 billion), an increase of 28 percent, and an operating profit of US$436 million (£276 million). Direct Energy is the North American subsidiary of Centrica plc (LSE: CNA). Centrica reported full year 2013 revenues of US$41.6 billion (£26.6 billion) with an operating profit of US$4.2 billion (£2.7 billion).

Novogen Announces Key Appointments to Drive Development of Anti-Tropomyosin Drug Platform
PR Newswire - Mon Feb 03, 11:30AM CST
Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced the appointments of Justine Stehn, PhD and Professor Peter Gunning, PhD to roles within the Company. Dr. Stehn and Professor Gunning are the co-inventors of the anti-tropomyosin (ATM) drug technology platform that Novogen acquired in 2013, and their appointments are an important step in realizing the significant potential of this new drug platform in treating cancer.

Novogen to Host Corporate Update and Webcast
PR Newswire - Thu Jan 30, 5:54PM CST
Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced it will host a corporate update with Graham Kelly, Ph.D., Novogen Group Executive Chairman and Chief Executive Officer, and David Brown, Ph.D., Chief Scientific Officer on Friday, February 7, 2014 at 8:00 a.m. (Sydney local time). This corresponds to Thursday, February 6, 2014 at 4:00 p.m. U.S. Eastern Standard Time.

Novogen to Present at Biotech Showcase(TM) 2014
PR Newswire - Wed Jan 08, 6:30AM CST
Novogen Limited (ASX:NRT; NASDAQ:NVGN), an oncology drug development company, today announced that Graham Kelly, Ph.D., its Executive Chairman and Chief Executive Officer, is scheduled to present a company overview to investors, pharmaceutical and healthcare executives attending the Biotech Showcase(TM) 2014, taking place January 13-15, 2014 in San Francisco, Calif.

Novogen Announces Establishment of Global Collaboration to Drive The Development of Drugs to Treat Brain Cancer
PR Newswire - Fri Dec 20, 7:00AM CST
Novogen Limited, an oncology drug development company, announced today the signing of a Sponsored Research Agreement with Cornell University. The Weill Cornell Medical College (WCMC) in New York will become the cornerstone of a collaboration across Europe, US, Asia and Australia involving universities and biotechnology companies seeking a treatment capable of delivering long-term remission for the main form of primary brain cancer, glioblastoma multiforme (GBM).

Novogen files suite of patents in US for ATM drug technology
M2 - Wed Nov 27, 4:23AM CST
Australian biotechnology company Novogen Limited (ASX: NRT)(Nasdaq:NVGN) announced on Tuesday the filing of a family of provisional patents in the US covering anti-tropomyosin (ATM) drug technology.

Novogen Files Suite of Patents for Anti-Tropomyosin Drug Technology
PR Newswire - Tue Nov 26, 7:42AM CST
Novogen Limited (ASX: symbol NRT; Nasdaq: symbol NVGN) today announced the filing of a family of provisional patents in the US covering anti-tropomyosin (ATM) drug technology.

HIMX, GALE, INTC and NVGN added to NASDAQ Active Stock Watch List at GSR
ACCESSWIRE - Mon Nov 25, 9:16AM CST
New York, NY - (ACCESSWIRE) - 11/25/2013 - Growing Stock Report initiates its NASDAQ Active Stock Weekly Watch List adding Himax Technologies, Inc. (NASDAQ:HIMX), Galena Biopharma, Inc. (NASDAQ:GALE), Intel Corporation (NASDAQ:INTC) and Novogen Limited (NASDAQ:NVGN)

Novogen Launches Joint Venture Aimed At Developing Drugs to Fight Ovarian Cancer
PR Newswire - Wed Nov 06, 7:00AM CST
Novogen Limited (Australian Securities Exchange: NRT and NASDAQ: NVGN), an Australian biotechnology company dedicated to developing drugs that provide long-term remission through the successful control of cancer stem cells, today announced a joint venture with Yale University dedicated to developing personalized approaches to chemotherapy to fight ovarian cancer.

SNTA, DNDN, ZGNX and NVGN added to NASDAQ Active Stock Watch List at EPR
ACCESSWIRE - Mon Oct 28, 8:58AM CDT
New York, NY - (ACCESSWIRE) - 10/28/2013 - Equity Profile Report initiates its Health-care Active Stock Watch List adding Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Dendreon Corp. (NASDAQ NDN), Zogenix, Inc. (NASDAQ:ZGNX), and Novogen Limited (NASDAQ:NVGN)

Market Maker Surveillance Report. CKSW, NVGN, USU, NDLS, DQ, RNDY, Losing Stocks With Lowest Price Friction For Monday, July 8th 2013
M2 - Tue Jul 09, 4:23AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 3901 companies with "abnormal" market making, 2937 companies with positive Friction Factors and 2297 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Clicksoftware Technologies Ltd (NASDAQ:CKSW), Novogen Ltd (NASDAQ:NVGN), USEC Inc (NYSE:USU), NATIONAL DLR STORES (NASDAQ:NDLS), Daqo New Energy Corp (NYSE Q), Roundy's Inc (NYSE:RNDY). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks

Market Maker Surveillance Report. NURO, NVGN, ET, LOTE, INFI, BEAT, Winning Stocks With Lowest Price Friction For Tuesday, June 4th 2013
M2 - Wed Jun 05, 3:30AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3819 companies with "abnormal" market making, 2025 companies with positive Friction Factors and 3252 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. NeuroMetrix Inc (NASDAQ:NURO), Novogen Ltd (NASDAQ:NVGN), E*TRADE FINL CORP (NYSE:ET), LORIMAR TELEPICTURES (OTC:LOTE), Infinity Pharmaceuticals Inc (NASDAQ:INFI), CardioNet Inc (NASDAQ:BEAT). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

NVGN, AVEO, QQEW, Removed From Naked Short Lists Today
M2 - Mon May 20, 8:54AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Removed From the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Novogen Ltd (NASDAQ:NVGN), Aveo Pharmaceuticals Inc (NASDAQ:AVEO), First Trust Portfolios LP (NASDAQ:QQEW). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .

NVGN, ABIO, RVXCF, QQEW, Added To Naked Short Lists Today
M2 - Thu May 09, 8:54AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Added To the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Novogen Ltd (NASDAQ:NVGN), ARCA Biopharma Inc (NASDAQ:ABIO), RESVERLOGIX CORP (OTC:RVXCF), First Trust Portfolios LP (NASDAQ:QQEW). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading